{"url_path":"/sec/mira/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-023005-index.html","accession_number":"0001493152-26-023005","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-023005-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":315,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\nThe\ninformation called for by this Item is incorporated herein by reference to the Exhibit Index in this Form 10-Q.\n\n \n\n**Number**\n \n**Description**\n\n \n \n \n\n3.1\n \n[Third Amended and Restated Articles of Incorporation of MIRA Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form S-1 filed July 28, 2023).](https://www.sec.gov/Archives/edgar/data/1904286/000149315223022931/ex3-1.htm)\n\n3.2\n \n[Second Amended and Restated Bylaws of MIRA Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to Form 10-K filed March 31, 2026)](https://www.sec.gov/Archives/edgar/data/1904286/000149315226014001/ex3-2.htm)\n\n31.1*\n \n[Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-1.htm)\n\n31.2*\n\n \n[Certification of the Interim Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-2.htm)\n\n32.1**\n \n[Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm)\n\n32.2**\n \n[Certification of the Interim Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-2.htm)\n\n101.INS\n \nInline XBRL\nInstance Document\n\n101.SCH\n \nInline XBRL\nTaxonomy Extension Schema Document\n\n101.CAL\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF\n \nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n \nCover Page Interactive\nData File (embedded within the Inline XBRL document)\n\n \n\n*\nFiled\nherewith\n\n**\nFurnished\nherewith\n\n \n\n23\n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to\nbe signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n**MIRA\nPHARMACEUTICALS, INC.**\n\n \n \n \n\nDate:\nMay 14, 2026\nBy:\n*/s/\nErez Aminov*\n\n \nName:\n**Erez\nAminov**\n\n \nTitle:\n\n**Chief\nExecutive Officer**\n\n \n \n**(Principal\nExecutive Officer)**\n\nDate:\nMay 14, 2026\n \n \n\n \nBy:\n*/s/\nAlan Weichselbaum*\n\n \nName:\n**Alan\nWeichselbaum**\n\n \nTitle:\n**Chief\nFinancial Officer**\n\n \n \n**(Principal\nFinancial Officer)**\n\n \n\n24"}